bioRxivImmunologyPreprint
Integration of immunomonitoring assays with PET/CT in TB patients identifies on-treatment biomarkers
Jingwen FaniD, Vincent RouillyiD, Munyaradzi MusvosviiD, Marie RobertiD, Chloé Albert VegaiD, Vincent BondetiD, Annika Jasper, Xiang YuiD, Stephanus Theron MalherbeiD, Raphaël BorieiD, Nathan Peiffer‐SmadjaiD, Karim SacréiD, Benjamin TerrieriD, Gerhard WalzliD, Clifton E. BarryiD, Michele D. TamerisiD, Thomas J. ScribaiD, Darragh DuffyiD
Abstract
Tuberculosis (TB) continues to pose a significant global public health challenge with substantial patient morbidity and mortality. Current TB patient biomarkers lack sufficient resolution to inform treatment response and patient stratification. This necessitates the development of sensitive and reliable host biomarkers. We previously demonstrated the efficacy of TruCulture whole blood stimulation for differentiating asymptomatic TB from active pulmonary TB disease patients in endemic regions. Our systems immunology study expands upon this previous work by evaluating the potential of TruCulture to monitor longitudinal responses to TB treatment in patients from the Predict-TB trial before, during, and after 6 months of antibiotic therapy. We stimulated whole blood from TB patients (n=40) using TruCulture under four conditions (Null, Mycobacterium tuberculosis-antigen, LPS, and IL-1{beta}) at baseline (week 0), during treatment (weeks 16 and 24), and one-year follow-up post- treatment (week 72). 20/25 measured cytokines exhibited significant changes throughout treatment, with several continuing to evolve during post-therapy follow-up. Machine learning based analysis identified Mtb-Ag-induced IL-1RA (AUC = 0.90, 0.92, 0.95 at weeks 16, 24, 72) and LPS-induced NLRP3 (AUC = 0.94 at week 16) as the best protein and transcriptional biomarkers for distinguishing treated from untreated patients, strongly implicating the inflammasome response. Combining these results with the extent of lung disease assessed by FDG PET/CT scans, we showed direct disease relevance for these blood-based biomarkers. The identified biomarker profiles hold promise for improving TB patient care through early prediction of treatment responses, real-time therapy monitoring, and informed development of host-directed therapeutic strategies for clinical decision-making. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=146 HEIGHT=200 SRC="FIGDIR/small/723467v1_ufig1.gif" ALT="Figure 1"> View larger version (45K): org.highwire.dtl.DTLVardef@15ae804org.highwire.dtl.DTLVardef@136939forg.highwire.dtl.DTLVardef@15ac58org.highwire.dtl.DTLVardef@e5d8f0_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstractC_FLOATNO Predict-TB clinical study overview and summary of TB-specific biomarkers identified from TruCulture whole blood stimulation system. C_FIG
- organism: human
- assay: proteomics
- research focus: cell type annotation
- approach: machine learning (classical)
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune profiling in M. tuberculosis infection enables stratification of patients with active disease
D. Duffy, E. Nemes, … M. L. Albert·bioRxiv·Mar 18, 2019
- In-depth immunophenotyping with mass cytometry during TB treatment reveals non-canonical T-cell subsets associated with sputum culture conversion.
C. Chedid, T. Andrieu, … F. Ader·bioRxiv·Oct 27, 2021
- Tuberculosis alters immune-metabolic pathways resulting in perturbed IL-1 responses
- Whole blood transcriptional responses associated with bacterial burden in pulmonary tuberculosis
Le Thanh Hoang Nhat, Triet Minh Thai, … Nguyễn Thụy Thương Thương·bioRxiv·Jan 29, 2026
- High Dimensional Immune Profiling Reveals CD39 as a Correlate of Tuberculosis Disease Severity
Jacqueline Watt, Dustin Sokolowski, … Jun Liu·bioRxiv·Jul 7, 2026
- Pathogen and host biomarkers to aid early diagnosis and prognosis of tuberculous meningitis
Urvashi Balbir Singh, K. P. Angitha, … Uma Kanga·InfectionPeer-reviewed·Oct 8, 2026